Published in Blood Weekly, October 30th, 2003
In a recent study, scientists in the United States "reviewed the clinical outcome of eight patients with steroid-refractory chronic graft-versus-host disease (GVHD) who received an anti-CD20 chimeric monoclonal antibody (rituximab)."
"Rituximab was given by intravenous infusion at a weekly dose of 375 mg/m2 for 4 weeks," noted V. Ratanatharathorn and coauthors at the University of Michigan Cancer Center. "All patients had received extensive treatment with various immunosuppressive agents; six patients had also received...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.